JP7029401B2 - 抗ｒｏｒ１抗体およびその使用 - Google Patents
抗ｒｏｒ１抗体およびその使用 Download PDFInfo
- Publication number
- JP7029401B2 JP7029401B2 JP2018539977A JP2018539977A JP7029401B2 JP 7029401 B2 JP7029401 B2 JP 7029401B2 JP 2018539977 A JP2018539977 A JP 2018539977A JP 2018539977 A JP2018539977 A JP 2018539977A JP 7029401 B2 JP7029401 B2 JP 7029401B2
- Authority
- JP
- Japan
- Prior art keywords
- ror1
- binding protein
- binding
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 526
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 515
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 507
- 102000023732 binding proteins Human genes 0.000 claims description 295
- 108091008324 binding proteins Proteins 0.000 claims description 295
- 210000004027 cell Anatomy 0.000 claims description 274
- 238000009739 binding Methods 0.000 claims description 152
- 230000027455 binding Effects 0.000 claims description 151
- 238000000034 method Methods 0.000 claims description 128
- 230000014509 gene expression Effects 0.000 claims description 114
- 239000000523 sample Substances 0.000 claims description 112
- 206010028980 Neoplasm Diseases 0.000 claims description 111
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 80
- 239000012634 fragment Substances 0.000 claims description 79
- 108090000623 proteins and genes Proteins 0.000 claims description 78
- 239000000427 antigen Substances 0.000 claims description 75
- 108091007433 antigens Proteins 0.000 claims description 75
- 102000036639 antigens Human genes 0.000 claims description 75
- 102000004169 proteins and genes Human genes 0.000 claims description 69
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 68
- 201000010099 disease Diseases 0.000 claims description 57
- 230000009870 specific binding Effects 0.000 claims description 55
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 53
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 49
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 49
- 238000003364 immunohistochemistry Methods 0.000 claims description 46
- 238000002560 therapeutic procedure Methods 0.000 claims description 45
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 39
- 238000011282 treatment Methods 0.000 claims description 38
- 102000040430 polynucleotide Human genes 0.000 claims description 37
- 108091033319 polynucleotide Proteins 0.000 claims description 37
- 239000002157 polynucleotide Substances 0.000 claims description 37
- 150000001413 amino acids Chemical group 0.000 claims description 36
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 35
- 238000003119 immunoblot Methods 0.000 claims description 35
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 26
- 208000020816 lung neoplasm Diseases 0.000 claims description 25
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 23
- 201000005202 lung cancer Diseases 0.000 claims description 23
- 206010006187 Breast cancer Diseases 0.000 claims description 21
- 208000026310 Breast neoplasm Diseases 0.000 claims description 21
- 206010033128 Ovarian cancer Diseases 0.000 claims description 20
- 230000008901 benefit Effects 0.000 claims description 19
- 239000012472 biological sample Substances 0.000 claims description 16
- 102000049583 human ROR1 Human genes 0.000 claims description 16
- 238000001514 detection method Methods 0.000 claims description 15
- 238000011467 adoptive cell therapy Methods 0.000 claims description 12
- 239000003550 marker Substances 0.000 claims description 10
- 238000004393 prognosis Methods 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 claims description 8
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 claims description 6
- 239000000975 dye Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 238000002659 cell therapy Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 238000010837 poor prognosis Methods 0.000 claims description 5
- 239000007850 fluorescent dye Substances 0.000 claims description 4
- 108010006700 Receptor Tyrosine Kinase-like Orphan Receptors Proteins 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 description 178
- 125000003275 alpha amino acid group Chemical group 0.000 description 107
- 238000010186 staining Methods 0.000 description 59
- 235000018102 proteins Nutrition 0.000 description 56
- 235000001014 amino acid Nutrition 0.000 description 49
- 150000007523 nucleic acids Chemical class 0.000 description 46
- 102000039446 nucleic acids Human genes 0.000 description 45
- 108020004707 nucleic acids Proteins 0.000 description 45
- 102000004196 processed proteins & peptides Human genes 0.000 description 37
- 229920001184 polypeptide Polymers 0.000 description 30
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 29
- 238000009169 immunotherapy Methods 0.000 description 25
- 239000013598 vector Substances 0.000 description 25
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 23
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 23
- 241000282560 Macaca mulatta Species 0.000 description 23
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 22
- 201000011510 cancer Diseases 0.000 description 20
- 201000005249 lung adenocarcinoma Diseases 0.000 description 20
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 19
- 210000004899 c-terminal region Anatomy 0.000 description 19
- 210000001165 lymph node Anatomy 0.000 description 19
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 19
- 230000003834 intracellular effect Effects 0.000 description 18
- 108060003951 Immunoglobulin Proteins 0.000 description 17
- 208000009956 adenocarcinoma Diseases 0.000 description 17
- 108020001507 fusion proteins Proteins 0.000 description 17
- 102000037865 fusion proteins Human genes 0.000 description 17
- 102000018358 immunoglobulin Human genes 0.000 description 17
- 108010029485 Protein Isoforms Proteins 0.000 description 16
- 102000001708 Protein Isoforms Human genes 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- 208000000649 small cell carcinoma Diseases 0.000 description 15
- 206010041823 squamous cell carcinoma Diseases 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- 208000002458 carcinoid tumor Diseases 0.000 description 14
- 210000001789 adipocyte Anatomy 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 230000003463 hyperproliferative effect Effects 0.000 description 13
- 210000004379 membrane Anatomy 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 206010061289 metastatic neoplasm Diseases 0.000 description 12
- 239000012188 paraffin wax Substances 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000006166 lysate Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 102000012515 Protein kinase domains Human genes 0.000 description 10
- 108050002122 Protein kinase domains Proteins 0.000 description 10
- 230000001394 metastastic effect Effects 0.000 description 10
- 210000002741 palatine tonsil Anatomy 0.000 description 10
- 210000002990 parathyroid gland Anatomy 0.000 description 10
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 210000003238 esophagus Anatomy 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241000282553 Macaca Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 238000011532 immunohistochemical staining Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 210000004153 islets of langerhan Anatomy 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 5
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 5
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 5
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 206010057248 Cell death Diseases 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000013074 reference sample Substances 0.000 description 4
- 238000002626 targeted therapy Methods 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 101100038118 Mus musculus Ror1 gene Proteins 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 102000028557 immunoglobulin binding proteins Human genes 0.000 description 3
- 108091009323 immunoglobulin binding proteins Proteins 0.000 description 3
- 238000013388 immunohistochemistry analysis Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 208000019694 serous adenocarcinoma Diseases 0.000 description 3
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229920000037 Polyproline Polymers 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 2
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- -1 fluidants Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 102000049622 human ROR2 Human genes 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000009126 molecular therapy Methods 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 108010026466 polyproline Proteins 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 210000004203 pyloric antrum Anatomy 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108091028075 Circular RNA Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000010772 Dog disease Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 208000005431 Endometrioid Carcinoma Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 102000018152 Frizzled domains Human genes 0.000 description 1
- 108050007261 Frizzled domains Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101100038117 Homo sapiens ROR1 gene Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 241000251471 Hydrolagus colliei Species 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 101150001095 ROR1 gene Proteins 0.000 description 1
- 102000005435 Receptor Tyrosine Kinase-like Orphan Receptors Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102220492414 Ribulose-phosphate 3-epimerase_H35A_mutation Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 101150106148 TOR1 gene Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000019493 atypical carcinoid tumor Diseases 0.000 description 1
- 208000005266 avian sarcoma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002804 saturated mutagenesis Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4251—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021196080A JP2022028918A (ja) | 2016-02-02 | 2021-12-02 | 抗ｒｏｒ１抗体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662290337P | 2016-02-02 | 2016-02-02 | |
| US62/290,337 | 2016-02-02 | ||
| US201662324876P | 2016-04-19 | 2016-04-19 | |
| US62/324,876 | 2016-04-19 | ||
| PCT/US2017/016300 WO2017136607A1 (en) | 2016-02-02 | 2017-02-02 | Anti-ror1 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021196080A Division JP2022028918A (ja) | 2016-02-02 | 2021-12-02 | 抗ｒｏｒ１抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511904A JP2019511904A (ja) | 2019-05-09 |
| JP2019511904A5 JP2019511904A5 (cg-RX-API-DMAC7.html) | 2020-03-12 |
| JP7029401B2 true JP7029401B2 (ja) | 2022-03-03 |
Family
ID=58054529
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539977A Active JP7029401B2 (ja) | 2016-02-02 | 2017-02-02 | 抗ｒｏｒ１抗体およびその使用 |
| JP2021196080A Pending JP2022028918A (ja) | 2016-02-02 | 2021-12-02 | 抗ｒｏｒ１抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021196080A Pending JP2022028918A (ja) | 2016-02-02 | 2021-12-02 | 抗ｒｏｒ１抗体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10968275B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3411408B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7029401B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108699149B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017213844A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3012827A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2903228T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018009011A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017136607A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016115559A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| SG11201803098VA (en) | 2015-10-30 | 2018-05-30 | Nbe Therapeutics Ag | Anti-ror1 antibodies |
| UA125718C2 (uk) | 2016-01-20 | 2022-05-25 | Зе Скріппс Ресеарч Інстітьют | Композиції антитіл до ror1 і пов'язані з ними способи |
| EP3411408B1 (en) | 2016-02-02 | 2021-12-08 | Fred Hutchinson Cancer Research Center | Anti-ror1 antibodies and uses thereof |
| EP3582782B1 (en) | 2017-02-17 | 2023-06-07 | Fred Hutchinson Cancer Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| BR112020002368A2 (pt) | 2017-08-07 | 2020-09-01 | Nbe-Therapeutics Ag | conjugados anticorpo-medicamento tendo alta tolerabilidade in vivo |
| PL3703750T3 (pl) | 2017-11-01 | 2025-04-07 | Juno Therapeutics, Inc. | Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy |
| WO2019090364A1 (en) | 2017-11-06 | 2019-05-09 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| EP3936523A4 (en) * | 2019-01-08 | 2022-09-07 | Shenzhen University | ANTIBODY DETECTION OF MALIGNANT TUMOR CELLS AND THEIR APPLICATIONS |
| BR112021014833A2 (pt) | 2019-01-29 | 2021-10-05 | Juno Therapeutics, Inc. | Anticorpos e receptores antigênicos quiméricos específicos para receptor órfão 1 de tipo tirosina quinase de receptor (ror1) |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| WO2023077026A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
| WO2023186100A1 (zh) * | 2022-04-02 | 2023-10-05 | 山东先声生物制药有限公司 | 抗ror1的抗体及其用途 |
| WO2024025343A1 (ko) * | 2022-07-26 | 2024-02-01 | (주)에임드바이오 | 항-ror1 항체 및 이의 용도 |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN115724973B (zh) * | 2022-09-26 | 2023-07-11 | 普健生物（武汉）科技有限公司 | 抗人ror1高亲和力兔单克隆抗体及其应用 |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN115894691A (zh) * | 2022-12-27 | 2023-04-04 | 上海医药集团生物治疗技术有限公司 | 靶向ror1的抗原结合蛋白 |
| AU2023418243A1 (en) * | 2022-12-27 | 2025-08-14 | Sph Biotherapeutics (Hk) Limited | Antigen-binding protein targeting ror1 |
| CN116183472B (zh) * | 2023-04-25 | 2023-08-18 | 上海益诺思生物技术股份有限公司 | Cba法检测非人类灵长类动物细胞因子的验证方法 |
| WO2025007910A1 (en) * | 2023-07-04 | 2025-01-09 | TJ Biopharma (Shanghai) Co., Ltd. | Anti-ror1 antibodies and uses thereof |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010005068A1 (ja) | 2008-07-10 | 2010-01-14 | 東レ株式会社 | 癌の治療及び予防用医薬組成物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA114536A (en) | 1908-09-18 | 1908-10-13 | Adolphe Chalas | Nickel recovering process |
| CA138293A (en) | 1911-11-06 | 1912-02-06 | Charles E. Archie | Variable speed gearing |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| WO2002002641A1 (en) | 2000-06-16 | 2002-01-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
| EP1497445A2 (en) | 2002-04-01 | 2005-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| WO2005035732A2 (en) | 2003-02-19 | 2005-04-21 | Dyax Corporation | Papp-a ligands |
| US20070274981A1 (en) | 2003-10-16 | 2007-11-29 | Imclone Systems Incorporation | Fibroblast Growth Factor Receptor-1 Inhibitors and Methods of Treatment Thereof |
| US7973139B2 (en) | 2004-03-26 | 2011-07-05 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| US9316646B2 (en) | 2009-04-23 | 2016-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ROR1 antibodies |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US9242014B2 (en) | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| US9163258B2 (en) | 2010-07-23 | 2015-10-20 | Fred Hutchinson Cancer Research Center | Method for the treatment of obesity |
| EP3219731A1 (en) | 2010-10-01 | 2017-09-20 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| WO2012075158A1 (en) | 2010-12-01 | 2012-06-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ror1 antibodies |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| MX359513B (es) | 2011-03-23 | 2018-10-01 | Hutchinson Fred Cancer Res | Metodo y composiciones para inmunoterapia celular. |
| JP6277126B2 (ja) | 2011-08-09 | 2018-02-07 | アセラ・バイオテクノロジーズ・アーベー | ホスホリルコリン（ｐｃ）および／またはｐｃコンジュゲートに結合する抗体 |
| JO3625B1 (ar) | 2011-09-22 | 2020-08-27 | Amgen Inc | بروتينات رابطة للأنتيجين cd27l |
| IL237315B (en) | 2012-08-20 | 2022-07-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
| ES2992753T3 (en) | 2012-08-24 | 2024-12-17 | Univ California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| WO2014164554A1 (en) | 2013-03-10 | 2014-10-09 | Baylor College Of Medicine | Chemotherapy-resistant immune cells |
| WO2016016344A1 (en) | 2014-07-29 | 2016-02-04 | Cellectis | Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy |
| AU2015339402B2 (en) | 2014-10-27 | 2021-08-26 | Fred Hutchinson Cancer Center | Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy |
| WO2016115559A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| CN108137669B (zh) | 2015-05-18 | 2023-02-17 | 优瑞科生物技术公司 | 抗ror1嵌合抗原受体 |
| EP3411408B1 (en) | 2016-02-02 | 2021-12-08 | Fred Hutchinson Cancer Research Center | Anti-ror1 antibodies and uses thereof |
| MA45341A (fr) | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
-
2017
- 2017-02-02 EP EP17705745.2A patent/EP3411408B1/en active Active
- 2017-02-02 MX MX2018009011A patent/MX2018009011A/es unknown
- 2017-02-02 CA CA3012827A patent/CA3012827A1/en active Pending
- 2017-02-02 CN CN201780009313.5A patent/CN108699149B/zh active Active
- 2017-02-02 JP JP2018539977A patent/JP7029401B2/ja active Active
- 2017-02-02 EP EP21204990.2A patent/EP4006056A1/en active Pending
- 2017-02-02 US US16/074,737 patent/US10968275B2/en active Active
- 2017-02-02 AU AU2017213844A patent/AU2017213844A1/en not_active Abandoned
- 2017-02-02 ES ES17705745T patent/ES2903228T3/es active Active
- 2017-02-02 WO PCT/US2017/016300 patent/WO2017136607A1/en not_active Ceased
-
2021
- 2021-01-25 US US17/157,810 patent/US11932691B2/en active Active
- 2021-12-02 JP JP2021196080A patent/JP2022028918A/ja active Pending
-
2024
- 2024-02-07 US US18/435,933 patent/US20240352119A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010005068A1 (ja) | 2008-07-10 | 2010-01-14 | 東レ株式会社 | 癌の治療及び予防用医薬組成物 |
Non-Patent Citations (4)
| Title |
|---|
| ANONYMOUS，ANTI-ROR1 ANTIBODY (RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTOR 1) (C-TERM)，ONLINE，2008年09月01日，PAGE(S):1-4，https://www.antibodies-online.com/productsheets/ABIN5539753.pdf |
| ANONYMOUS，PRODUCT DATASHEET: ARP63925_P050 - ROR1 ANTIBODY - C-TERMINAL REGION (ARP63925_P050)，AVIVA SYSTEMS BIOLOGY，2016年01月01日，PAGE(S):1-2，http://www.avivasysbio.com/sd/tds/html_datasheet.php?sku=ARP63925_P050 |
| Int. J. Cancer，2008年，Vol.123，p.1190-1195 |
| PLOS ONE，2011年，Vol.6, Issue6，e21018 |
Also Published As
| Publication number | Publication date |
|---|---|
| US11932691B2 (en) | 2024-03-19 |
| CN108699149B (zh) | 2023-01-06 |
| WO2017136607A1 (en) | 2017-08-10 |
| CN108699149A (zh) | 2018-10-23 |
| US10968275B2 (en) | 2021-04-06 |
| EP3411408B1 (en) | 2021-12-08 |
| AU2017213844A1 (en) | 2018-08-02 |
| EP3411408A1 (en) | 2018-12-12 |
| JP2019511904A (ja) | 2019-05-09 |
| JP2022028918A (ja) | 2022-02-16 |
| CA3012827A1 (en) | 2017-08-10 |
| US20190040132A1 (en) | 2019-02-07 |
| US20240352119A1 (en) | 2024-10-24 |
| MX2018009011A (es) | 2018-11-19 |
| US20210147540A1 (en) | 2021-05-20 |
| EP4006056A1 (en) | 2022-06-01 |
| ES2903228T3 (es) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240352119A1 (en) | Anti-ror1 antibodies and uses thereof | |
| US12162950B2 (en) | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis | |
| KR102056137B1 (ko) | 암의 검출 방법 | |
| CN104823054A (zh) | 对修饰后自体表位的抗肿瘤免疫应答 | |
| CN113004408B (zh) | 抗人程序死亡因子-1单克隆抗体 | |
| EP3239176A1 (en) | Anti-active gip antibody | |
| JP7437307B2 (ja) | ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１ | |
| KR20190091483A (ko) | 항-pcna 단클론성 항체 및 이의 용도 | |
| CN109970859B (zh) | Glypican-3特异性抗体及其特异性CAR-T细胞 | |
| JP2021529539A (ja) | 特定の自己免疫疾患を治療するためのｃｄ６標的キメラ抗原受容体 | |
| CN114258402B (zh) | 抗cd123抗体、抗cd123嵌合抗原受体和抗cd123嵌合抗原受体t细胞 | |
| JPWO2016052756A1 (ja) | 浸潤能の高い癌細胞の検出用又は診断用試薬 | |
| US12319749B2 (en) | Antibody and functional fragment thereof | |
| HK40075786A (en) | Anti-ror1 antibodies and uses thereof | |
| HK40000385B (en) | Anti-ror1 antibodies and uses thereof | |
| WO2026001907A1 (en) | Anti-nkg2a antibodies, fusion proteins and uses thereof | |
| NL2021034B1 (en) | TEIPP neoantigens and uses thereof | |
| HK40048285B (en) | Anti-human program death factor-1 monoclonal antibody | |
| HK40048285A (en) | Anti-human program death factor-1 monoclonal antibody | |
| JP7209284B2 (ja) | Ｔｍｅｍ１３２ａに結合する抗体、抗がん剤、およびがんの検査方法 | |
| KR20190107967A (ko) | 한국인 위암 연관 유전자 단클론 항체 및 이의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200203 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200203 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210120 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210415 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210527 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210802 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211202 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20211202 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20211210 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220112 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220113 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220201 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220218 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7029401 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |